| Literature DB >> 26064937 |
Shengchin Kao1, Hungchen Lee2, Chihwen Cheng1, Chingfeng Lin2, Hsini Tsai1.
Abstract
Background. Direct intra-articular injection of low doses of local anesthetic (IALA) after closure of the joint capsule remains controversial for pain control after total knee arthroplasty (TKA). Methods. A retrospective study comparing patients receiving IALA with high doses (0.5% bupivacaine 60 mL) of local anesthetics or FNB in addition to intravenous patient-controlled analgesia with opioids for pain management after TKA was conducted. The primary end point was to compare the analgesic efficacy and early ambulation between the two groups. Results. No significant differences between the two groups in pain intensity, cumulative opioid consumption, incidences of opioid-related side effects, the time interval from the end of operation to the first time the patient could walk assisted with a walker postoperatively, and postoperative hospital stay were identified. Three patients in the IALA group but none in the FNB group walked within 12 hours after the end of operation. Summary. IALA with high doses of local anesthetics provides comparable analgesic efficacy as single-shot FNB after TKA and might be associated with earlier ambulation than FNB postoperatively.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26064937 PMCID: PMC4433655 DOI: 10.1155/2015/649140
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Comparison of demographic and clinical data between IALA and FNB group.
| IALA group ( | FNB group ( |
| |
|---|---|---|---|
| Gender (male/female) | 9/30 | 7/48 | 0.266 |
| Age (y), mean (SD) | 68.41 (9.46) | 70.64 (8.00) | 0.221 |
| BMI (kg/m2), mean (SD) | 28.88 (7.12) | 28.05 (3.88) | 0.596 |
| ASA physical status | 0.076 | ||
| I | 3 (7.7) | 0 (0) | |
| II | 16 (41.0) | 30 (54.5) | |
| III | 20 (51.3) | 25 (45.5) | |
| Comorbidities | |||
| Pulmonary disease (%) | 0 (0) | 4 (7.3) | 0.139 |
| Cardiovascular disease (%) | 22 (56.4) | 38 (69.1) | 0.267 |
| Liver disease (%) | 5 (12.8) | 12 (21.8) | 0.293 |
| Renal disease (%) | 1 (2.6) | 0 (0) | 0.415 |
| Gastrointestinal disease (%) | 10 (47.6) | 47 (85.5) | <0.001 |
| Surgical approach | |||
| Medial parapatellar | 39 (100) | 55 (100) | N.A. |
| Implanted prosthesis | |||
| Tricompartment | 39 (100) | 55 (100) | N.A. |
| Prosthesis manufacturer | |||
| Zimmer | 39 (100) | 55 (100) | N.A. |
| Intraoperative opioids∗ (mg) | 16.28 (3.58) | 18.19 (4.92) | 0.037 |
| Intraoperative opioids∗/BW (mg/kg) | 0.24 ± 0.05 | 0.29 ± 0.08 | 0.0018 |
Categorical data were analyzed using Fisher's exact test. Continuous data were analyzed using t-test.
BMI: body mass index.
BW: body weight.
ASA: American Society Anesthesiologist.
∗Converted into i.v. equivalent dose of morphine.
Comparison of use of NSAIDs between IALA and FNB group.
| IALA group ( | FNB group ( |
| |
|---|---|---|---|
| Ketorolac 30 mg (i.v.) in PACU | 9 | 15 | 0.81 |
| Acetaminophen 500 mg QID in the ward | 39 | 55 | 1.000 |
| NSAIDs in the ward | 18 | 54 | <0.0001 |
| Aceclofenac 100 mg BID | 1 | 2 | |
| Acemetacin 90 mg QD | 0 | 1 | |
| Acemetacin 90 mg BID | 0 | 6 | |
| Celecoxib 200 mg QD | 0 | 29 | |
| Celecoxib 200 mg BID | 0 | 5 | |
| Diclofenac 25 mg TID | 0 | 1 | |
| Diclofenac 25 mg QID | 0 | 1 | |
| Etodolac 400 mg QD | 0 | 2 | |
| Etoricoxib 120 mg QD | 12 | 0 | |
| Mefenamic acid 250 mg QID | 0 | 4 | |
| Naproxen 250 mg BID | 0 | 1 | |
| Parecoxib 40 mg Q12 H | 5 | 2 |
BID: twice daily; TID: thrice daily; QID: 4 times a day; Q12 H: every 12 hours.
Postoperative pain intensity, cumulative opioid consumption, incidences of opioid-related side effects, time to ambulation, early ambulation, and hospital stay.
| IALA group ( | FNB group ( |
| |
|---|---|---|---|
| Verbal pain intensity scale∗ | |||
| POD1 (0/1/2/3/4) | 0/34/4/1/0 | 0/51/3/1/0 | 0.622 |
| POD2 (0/1/2/3/4) | 0/37/1/0/0 | 0/48/0/0/0 | 0.442 |
| Cumulative opioid consumption∗∗ | |||
| POD1 (mg), mean (SD) | 38.21 (18.36) | 35.55 (14.69) | 0.437 |
| POD2 (mg), mean (SD) | 69.28 (33.43) | 59.56 (29.40) | 0.142 |
| Cumulative opioid consumption∗∗/BW | |||
| POD1 (mg/kg), mean (SD) | 0.54 (0.23) | 0.56 (0.26) | 0.801 |
| POD2 (mg/kg), mean (SD) | 0.98 (0.43) | 0.99 (0.48) | 0.919 |
| Opioid related side effects∗∗∗ | |||
| Dizziness (%) | 5 (12.8) | 6 (10.9) | 1.000 |
| Nausea (%) | 2 (5.1) | 3 (5.5) | 1.000 |
| Vomiting (%) | 4 (10.3) | 3 (5.5) | 0.444 |
| Time to walk (hrs), mean (SD)∗∗∗∗ | 33 (14) | 35 (17) | 0.68 |
| Early ambulation (<12 hrs) | 3 | 0 | 0.07 |
| Postop hospital stay (day), mean (SD) | 4.18 (0.91) | 4.51 (1.41) | 0.205 |
Categorical data were analyzed using Fisher's exact test. Continuous data were analyzed using t-test.
BW: body weight (kg).
POD1: postoperative day 1.
POD2: postoperative day 2.
∗Verbal pain intensity scale: 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain, and 4 = extreme pain.
∗∗Converted to i.v. equivalent dose of morphine.
∗∗∗No pruritus or respiratory depression was recorded in both groups.
∗∗∗∗The time interval from the end of operation to postoperatively first time walking assisted with a walker.
Summary of previous studies on IALA.
| Authors, years | Drugs and doses for IA injection (total volume) | Pain intensity | Opioid consumption |
|---|---|---|---|
|
Badner et al., 1996 [ | 2 groups (30 mL) | No difference in the first 24 h | ↓ in the first 24 h |
| Mauerhan et al., 1997 [ | 4 groups (30 mL) | ↓ in the first 4 h | No difference in the first 24 h |
| Ritter et al., 1999 [ | 4 groups (10 mL) | No difference in the first 24 h | No difference in the first 24 h |
| Tanaka et al., 2001 [ | 2 groups for OA knee (30 mL) | ↓ in the first 24 h | ↓ in the first 48 h |
| Browne et al., 2004 [ | 2 groups (20 mL) | Insignificant ↓ in the first 24 h ( | No difference in the first 24 h |
| Rosen et al., 2010 [ | 2 groups (100 mL) | No difference in the first 24 h | No difference in the first 24 h |
∗With epinephrine 1 : 200,000.